

**ASX Announcement**  
**31 March 2025 (Melbourne, Australia)**  
**Optiscan Imaging Ltd (ASX:OIL)**

## **Optiscan Announces New CFO & Other Executive Appointments**

**These senior executive team changes mean Optiscan is now better resourced to implement its transformation plan and future-focussed priorities.**

### **Highlights**

- Optiscan's current Finance Manager, Mr Darius Ooi, has been promoted to the Chief Financial Officer role, and will now lead the Corporate team.
- Ms Belinda Williamson has been appointed as Chief Commercial Officer, and will head Optiscan's Customer team and lead the Company's efforts to derive value from its expanding commercial opportunities.
- Ms Jessica Ward has been appointed Optiscan's US-based Director of Clinical & Regulatory Affairs, and will manage the Company's burgeoning clinical and regulatory portfolios and lead its Clinical team.
- Optiscan has consolidated the US Business Development team for its life sciences product.
- Optiscan's Chief Operating Officer Brendan Fafiani has decided to step down from this role to pursue other opportunities.

**Optiscan Imaging Limited (ASX:OIL)** ('Optiscan' or the 'Company') is pleased to announce a reorganisation of its executive team. Post this revamp, the Company will be better placed to both successfully deliver on its stated transformation, clinical and regulatory strategies, and develop a number of exciting products currently in the pipeline.

### **Optiscan executive team changes are the result of an operational review**

Optiscan has recently completed a comprehensive review of its operations, sales and marketing functions, and clinical and regulatory strategy. A key outcome from this broad-ranging review process was an identified need for Optiscan to realign its Customer (Sales & Marketing), Clinical (Clinical & Regulatory), and Corporate (Finance, Info Technology, Investor Relations/Public Relations) teams in order to meet its stated objectives. To realise this realignment of key corporate responsibilities, the Company has taken steps to consolidate and refocus these functions internally to maintain agility, while building additional support and resources by engaging domain experts, consultants and advisors with deep experience in the US MedTech market.

### **A significantly enhanced Optiscan senior executive team now in place**

The Company's Finance Manager, Mr Darius Ooi, has been promoted to Chief Financial Officer, and has assumed responsibility of the Corporate team. Darius has been with the Company for nearly three years and

has led the transformation of the Finance function to support the Company's global strategy with an expanding product portfolio. He is an experienced Chartered Accountant who has worked with a variety of businesses, ranging from small enterprises to large corporations, adeptly navigating the complexities of finance and business operations. In his previous role at a large multinational medical device company, Darius played a pivotal role in several transformation projects that significantly contributed to revenue growth and operational efficiency. At Optiscan, Darius has already built a track record for successfully delivering multiple finance-related initiatives and has been instrumental in developing long-term financial strategies aligned to the Company's transformation journey. All this while managing capital expenditure, managing risk and compliance responsibilities, and playing a key role in the Company's investor- and corporate relations-related tasks.

In an Australia-based appointment, Ms Belinda Williamson has been appointed to the position of Chief Commercial Officer. In this role, Belinda will lead Optiscan's Sales and Marketing team and steer the Company's efforts to realise the value of the Company's expanding catalogue of commercial opportunities. Belinda is a dynamic people leader with a proven track record of leading and managing teams that consistently deliver outstanding growth in sales revenue and market share within the global health care delivery and medical device industry. She was previously Group Sales Manager Medical and National Sales Manager (Surgical Division) at Olympus Medical, and Regional Sales Manager and Strategic Account Manager at Johnson & Johnson Medical. She earlier held sales and marketing roles at Guidant Corporation, Boston Scientific, Bard Australia and Zimmer Australia.

Following the departure of Ms Nicole Williams and Mr Ken Lock, Optiscan has appointed Ms Jessica Ward as its US-based Director of Clinical & Regulatory Affairs to manage the Company's burgeoning clinical and regulatory portfolios in Australia, Germany and the US, and lead the Clinical team. Her initial focus will be the successful execution of upcoming clinical trials for US FDA regulatory clearance of Optiscan's new imaging solutions for surgery and pathology. Jessica is a seasoned leader who has successfully driven global clinical and medical affairs initiatives for a number of renowned organisations, including the Stryker Corporation and Atrium Health. Most recently, she led clinical and medical affairs teams at Stryker Instruments, overseeing a wide range of global projects specialising in developing clinical evidence generation strategies to support global regulatory clearances across diverse medical specialties, including Orthopaedic, Neurosurgical, ENT, and Interventional Pain.

The Company's US Business Development team for its life sciences product, ViewnVivo® has also undergone consolidation. This process has seen the departure of Mr Tim Rowe, and the retention of Ms Shayra Leon who will assume responsibility for this product line in the US, as well as Optiscan's new veterinary product which is progressing through the product pipeline.

Separately, Mr Brendan Fafiani has decided to step down as Optiscan's Chief Operating Officer. He has worked closely with Optiscan's leadership team to ensure a smooth and structured transition.

**Optiscan CEO and Managing Director, Dr Camile Farah, said:** "I want to congratulate Darius on his promotion. Darius' elevation to Optiscan's CFO follows his key role in transforming our Finance function

into one that better serves the Company's growing product portfolio and geographic footprint. Belinda's appointment as Optiscan's Chief Commercial Officer will help the Company realise the value embodied in its expanding catalogue of commercial opportunities. Jessica's appointment as our US-based Director of Clinical & Regulatory Affairs is a clear boost to our efforts to progress the Company's ever-expanding clinical and regulatory portfolios across all of our targeted geographic markets, with US FDA regulatory clearance being her initial focus.

I want to take this opportunity to thank Brendan, Tim, Nicole, and Ken for their respective contributions to Optiscan's evolution from a commercial, clinical and regulatory perspective during their time in the Company. I wish them well in their future endeavours.

With the deliberate realignment of Optiscan's human capital and structure actioned, the Company is now well-placed to meet the clinical, regulatory and commercial realities stemming from its evolving hardware and software product portfolio. I am confident that we have the leadership team in place to deliver on our ambitious transformation plan. Together we will be aggressively pursuing our goals to create value for our patients, customers and shareholders."

– ends –

This announcement has been authorised for release by the Board of Optiscan.

**For further information, please contact:**

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

T: +61 3 9538 3333

E: [ceo@optiscan.com](mailto:ceo@optiscan.com)

Media & Investor Enquiries

The Capital Network

Julia Maguire

T: +61 2 7257 7338

E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

**About Optiscan**

Optiscan Imaging Ltd (ASX: OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* digital imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high-resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

To learn more about Optiscan, visit [www.optiscan.com](http://www.optiscan.com) or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

**Optiscan Imaging Ltd (ASX:OIL)**

16 Miles St, Mulgrave VIC 3170, Australia • [www.optiscan.com](http://www.optiscan.com) • ABN: 81 077 771 987

## **Disclaimer**

*All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as ‘anticipate’, ‘believe’, ‘could’, ‘estimate’, ‘expect’, ‘future’, ‘intend’, ‘may’, ‘opportunity’, ‘plan’, ‘potential’, ‘project’, ‘seek’, ‘will’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.*